Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
; ^" F$ B: K+ _NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 4 ]: l x: t9 e6 k
+ Author Affiliations
7 A' d3 A! S* T4 O( b5 g6 m" {# x& _7 Y8 k$ K9 ~
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 4 F% w+ {, f6 r/ d s- l J' {' v
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 M G) P3 x5 G8 R$ k3 T# J
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ; E- i% F) S9 P7 p8 [3 N
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ! `4 {0 X& v& \6 {, p$ N
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 4 W! C! z6 m, D3 Z8 i
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 T2 w" Q3 O5 r7Kinki University School of Medicine, Osaka 589-8511, Japan
6 e$ h7 a, M' {8Izumi Municipal Hospital, Osaka 594-0071, Japan & H$ |: `! G9 X# B$ E3 B
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 1 d4 _& {0 h' U
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 A" L3 c* p) d5 {( L' [7 JAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
# Q. n& n' r$ c. v- k7 W K# U
$ H) F0 d% K/ Q; z |